Literature DB >> 2686903

Choice of anticoagulant in a congenital antithrombin III (AT III)-deficient patient with chronic renal failure undergoing regular haemodialysis.

T Matsuo1, T Yamada, T Yamanashi, K Kodama.   

Abstract

We describe a 43-year-old male patient with congenital antithrombin III deficiency requiring haemodialysis due to extension of venous thrombus from recurrent deep vein thrombosis. During dialysis with adequate heparinization, the patient often revealed clot formation in the extracorporeal circuit resulting in unexpected discontinuation of dialysis. When either a combination of antithrombin III concentrate plus heparin or the newly developed synthetic antithrombin preparation, MD805, was infused during dialysis, he could be uneventfully dialysed with either of the two regimens. The functional antithrombin III activity with MD805 increased to the same level as that obtained with antithrombin III concentrate, and it was possible to achieve an antithrombotic effect, as measured from the APTT and thrombin-antithrombin III complex with MD805 during and after dialysis. We thus found that MD805 could be used as an anticoagulant drug when an AT III-deficient patient required anticoagulation in the extracorporeal circulation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2686903     DOI: 10.1111/j.1365-2257.1989.tb00211.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  2 in total

Review 1.  A synopsis of the clinical uses of argatroban.

Authors:  M Moledina; M Chakir; P J Gandhi
Journal:  J Thromb Thrombolysis       Date:  2001-10       Impact factor: 2.300

2.  Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.